Literature DB >> 34210413

Supplemental Association of Clonal Hematopoiesis With Incident Heart Failure.

Bing Yu1, Mary B Roberts2, Laura M Raffield3, Seyedeh Maryam Zekavat4, Ngoc Quynh H Nguyen1, Mary L Biggs5, Michael R Brown1, Gabriel Griffin6, Pinkal Desai7, Adolfo Correa8, Alanna C Morrison1, Amil M Shah9, Abhishek Niroula10, Md Mesbah Uddin11, Michael C Honigberg12, Benjamin L Ebert13, Bruce M Psaty14, Eric A Whitsel15, JoAnn E Manson16, Charles Kooperberg17, Alexander G Bick18, Christie M Ballantyne19, Alex P Reiner17, Pradeep Natarajan20, Charles B Eaton21.   

Abstract

BACKGROUND: Age-related clonal hematopoiesis of indeterminate potential (CHIP), defined as clonally expanded leukemogenic sequence variations (particularly in DNMT3A, TET2, ASXL1, and JAK2) in asymptomatic individuals, is associated with cardiovascular events, including recurrent heart failure (HF).
OBJECTIVES: This study sought to evaluate whether CHIP is associated with incident HF.
METHODS: CHIP status was obtained from whole exome or genome sequencing of blood DNA in participants without prevalent HF or hematological malignancy from 5 cohorts. Cox proportional hazards models were performed within each cohort, adjusting for demographic and clinical risk factors, followed by fixed-effect meta-analyses. Large CHIP clones (defined as variant allele frequency >10%), HF with or without baseline coronary heart disease, and left ventricular ejection fraction were evaluated in secondary analyses.
RESULTS: Of 56,597 individuals (59% women, mean age 58 years at baseline), 3,406 (6%) had CHIP, and 4,694 developed HF (8.3%) over up to 20 years of follow-up. CHIP was prospectively associated with a 25% increased risk of HF in meta-analysis (hazard ratio: 1.25; 95% confidence interval: 1.13-1.38) with consistent associations across cohorts. ASXL1, TET2, and JAK2 sequence variations were each associated with an increased risk of HF, whereas DNMT3A sequence variations were not associated with HF. Secondary analyses suggested large CHIP was associated with a greater risk of HF (hazard ratio: 1.29; 95% confidence interval: 1.15-1.44), and the associations for CHIP on HF with and without prior coronary heart disease were homogenous. ASXL1 sequence variations were associated with reduced left ventricular ejection fraction.
CONCLUSIONS: CHIP, particularly sequence variations in ASXL1, TET2, and JAK2, represents a new risk factor for HF.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clonal hematopoiesis of indeterminate potential; heart failure; risk factor

Mesh:

Substances:

Year:  2021        PMID: 34210413      PMCID: PMC8313294          DOI: 10.1016/j.jacc.2021.04.085

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   27.203


  36 in total

1.  Multiple Somatic Mutations for Clonal Hematopoiesis Are Associated With Increased Mortality in Patients With Chronic Heart Failure.

Authors:  Sebastian Cremer; Klara Kirschbaum; Alexander Berkowitsch; David John; Katharina Kiefer; Lena Dorsheimer; Julian Wagner; Tina Rasper; Khalil Abou-El-Ardat; Birgit Assmus; Hubert Serve; Michael Rieger; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Circ Genom Precis Med       Date:  2020-06-29

2.  Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers.

Authors:  Benjamin L Ebert; Peter Libby
Journal:  Ann Intern Med       Date:  2018-05-29       Impact factor: 25.391

3.  Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure.

Authors:  Wesley Tyler Abplanalp; Silvia Mas-Peiro; Sebastian Cremer; David John; Stefanie Dimmeler; Andreas M Zeiher
Journal:  JAMA Cardiol       Date:  2020-10-01       Impact factor: 14.676

Review 4.  60 Years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations.

Authors:  Sami Ayachi; Manuel Buscarlet; Lambert Busque
Journal:  Exp Hematol       Date:  2020-01-28       Impact factor: 3.084

5.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Authors:  Felicitas Thol; Inna Friesen; Frederik Damm; Haiyang Yun; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Anuhar Chaturvedi; Amit Sharma; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Michael Heuser; Arnold Ganser
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

6.  Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction.

Authors:  Ying Wang; Soichi Sano; Yoshimitsu Yura; Zhonghe Ke; Miho Sano; Kosei Oshima; Hayato Ogawa; Keita Horitani; Kyung-Duk Min; Emiri Miura-Yura; Anupreet Kour; Megan A Evans; Maria A Zuriaga; Karen K Hirschi; Jose J Fuster; Eric M Pietras; Kenneth Walsh
Journal:  JCI Insight       Date:  2020-03-26

7.  Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project.

Authors:  Mark D Huffman; Jarett D Berry; Hongyan Ning; Alan R Dyer; Daniel B Garside; Xuan Cai; Martha L Daviglus; Donald M Lloyd-Jones
Journal:  J Am Coll Cardiol       Date:  2013-04-09       Impact factor: 24.094

Review 8.  Clonal hematopoiesis in human aging and disease.

Authors:  Siddhartha Jaiswal; Benjamin L Ebert
Journal:  Science       Date:  2019-11-01       Impact factor: 47.728

9.  Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure.

Authors:  Lena Dorsheimer; Birgit Assmus; Tina Rasper; Christina A Ortmann; Andreas Ecke; Khalil Abou-El-Ardat; Tobias Schmid; Bernhard Brüne; Sebastian Wagner; Hubert Serve; Jedrzej Hoffmann; Florian Seeger; Stefanie Dimmeler; Andreas M Zeiher; Michael A Rieger
Journal:  JAMA Cardiol       Date:  2019-01-01       Impact factor: 14.676

10.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.

Authors:  Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz
Journal:  Nat Biotechnol       Date:  2013-02-10       Impact factor: 54.908

View more
  13 in total

Review 1.  Somatic Mutations in Cardiovascular Disease.

Authors:  J Brett Heimlich; Alexander G Bick
Journal:  Circ Res       Date:  2022-01-07       Impact factor: 17.367

2.  Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality.

Authors:  Soichi Sano; Keita Horitani; Hayato Ogawa; Jonatan Halvardson; Nicholas W Chavkin; Ying Wang; Miho Sano; Jonas Mattisson; Atsushi Hata; Marcus Danielsson; Emiri Miura-Yura; Ammar Zaghlool; Megan A Evans; Tove Fall; Henry N De Hoyos; Johan Sundström; Yoshimitsu Yura; Anupreet Kour; Yohei Arai; Mark C Thel; Yuka Arai; Josyf C Mychaleckyj; Karen K Hirschi; Lars A Forsberg; Kenneth Walsh
Journal:  Science       Date:  2022-07-14       Impact factor: 63.714

Review 3.  Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease.

Authors:  Yoshimitsu Yura; Jesse D Cochran; Kenneth Walsh
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

Review 4.  Clonal hematopoiesis: Mutation-specific adaptation to environmental change.

Authors:  Marcus A Florez; Brandon T Tran; Trisha K Wathan; James DeGregori; Eric M Pietras; Katherine Y King
Journal:  Cell Stem Cell       Date:  2022-06-02       Impact factor: 25.269

Review 5.  Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans.

Authors:  Kenneth Walsh; Nalini Raghavachari; Candace Kerr; Alexander G Bick; Steven R Cummings; Todd Druley; Cynthia E Dunbar; Giulio Genovese; Margaret A Goodell; Siddhartha Jaiswal; Jaroslaw Maciejewski; Pradeep Natarajan; Anastasia V Shindyapina; Alan R Shuldiner; Erik B Van Den Akker; Jan Vijg
Journal:  Front Aging       Date:  2022-03-08

Review 6.  Clonal hematopoiesis and vascular disease.

Authors:  Kaushik Amancherla; John A Wells; Alexander G Bick
Journal:  Semin Immunopathol       Date:  2022-02-04       Impact factor: 11.759

7.  Clonal Hematopoiesis Is Associated With Higher Risk of Stroke.

Authors:  Romit Bhattacharya; Seyedeh M Zekavat; Jeffrey Haessler; Myriam Fornage; Laura Raffield; Md Mesbah Uddin; Alexander G Bick; Abhishek Niroula; Bing Yu; Christopher Gibson; Gabriel Griffin; Alanna C Morrison; Bruce M Psaty; William T Longstreth; Joshua C Bis; Stephen S Rich; Jerome I Rotter; Russell P Tracy; Adolfo Correa; Sudha Seshadri; Andrew Johnson; Jason M Collins; Kathleen M Hayden; Tracy E Madsen; Christie M Ballantyne; Siddhartha Jaiswal; Benjamin L Ebert; Charles Kooperberg; JoAnn E Manson; Eric A Whitsel; Pradeep Natarajan; Alexander P Reiner
Journal:  Stroke       Date:  2021-11-08       Impact factor: 10.170

Review 8.  Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease.

Authors:  Isidoro Cobo; Tiffany Tanaka; Christopher K Glass; Calvin Yeang
Journal:  Curr Opin Hematol       Date:  2022-01-01       Impact factor: 3.284

9.  Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study.

Authors:  Sara Denicolò; Verena Vogi; Felix Keller; Stefanie Thöni; Susanne Eder; Hiddo J L Heerspink; László Rosivall; Andrzej Wiecek; Patrick B Mark; Paul Perco; Johannes Leierer; Andreas Kronbichler; Marion Steger; Simon Schwendinger; Johannes Zschocke; Gert Mayer; Emina Jukic
Journal:  Kidney Int Rep       Date:  2022-02-03

Review 10.  Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease.

Authors:  Gregor Hoermann
Journal:  Diagnostics (Basel)       Date:  2022-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.